Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma

Dogan Vatansever; Hamdullah Sozen; Gulcin Sahin Ersoy; Burak Giray; Samet Topuz; A Cem Iyibozkurt; Yavuz Salihoglu

doi:10.1155/2020/1295613

Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma

J Oncol. 2020 Apr 10:2020:1295613. doi: 10.1155/2020/1295613. eCollection 2020.

Authors

Dogan Vatansever¹, Hamdullah Sozen², Gulcin Sahin Ersoy³, Burak Giray⁴, Samet Topuz², A Cem Iyibozkurt², Yavuz Salihoglu²

Affiliations

¹ Department of Obstetrics and Gynecology, Gynecologic Oncology Division, Koc University School of Medicine, Istanbul, Turkey.
² Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University, Istanbul, Turkey.
³ Department of Obstetrics and Gynecology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey.
⁴ Department of Obstetrics and Gynecology, Zeynep Kamil Education and Research Hospital, Istanbul, Turkey.

Abstract

Purpose: We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma.

Methods: We evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection.

Results: Overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0.28, 95% CI 0.13-0.62 p=0.002 for OS and hazard ratio 0.31, 95% CI 0.14-0.69 p=0.004 for RFS). Multivariate analysis showed that lymph node dissection, age, lymph node metastasis, and adjuvant therapy were independent prognostic variables of OS and RFS.

Conclusions: Systematic pelvic and paraaortic lymph node dissection independently and significantly prolongs the survival of patients with early-stage type II endometrial carcinoma and carcinosarcoma.